Elevated plasma levels of tissue factor (TF) and tissue factor pathway inhi
bitor (TFPI) and large amounts of monocyte procoagulant activity (PCA) have
been documented in unstable angina (UA) patients. In in vitro experiments
heparin is able to blunt monocyte TF production by inhibiting TF and cytoki
ne gene expression by stimulated cells and after in vivo administration it
reduces adverse ischemic outcomes in UA patients. TF and TFPI plasma levels
and monocyte PCA have been investigated in 28 refractory UA patients befor
e and during anticoagulant subcutaneous heparin administration (thrice dail
y weight- and PTT-adjusted for 3 days) followed by 5000 IU X 3 for 5 days.
After 2-day treatment, immediately prior to the heparin injection, TF and T
FPI plasma levels [(median and range): 239 pg/ml, 130-385 pg/ mi and 120 ng
/ml, 80-287 ng/ml] were lower in comparison to baseline samples (254.5 pg/m
l, 134.6-380 pg/ml and 135.5 ng/ml, 74-306 ng/ml). Four h after the heparin
injection TF furtherly decreased (176.5 pg/ml, 87.5-321 pg/ml; -32.5%, p<0
.001) and TFPI increased (240.5 ng/ml, 140-450 ng/ml; +67%, p<0.0001).
After 7-day treatment, before the injection of heparin, TF and TFPI plasma
levels (200 pg/ml, 128-325 pg/ml and 115 ng/ml, 70-252 ng/ml) significantly
decreased (p<0.05) in comparison to the pre-treatment values. On the morni
ng of the 8th day, 4 h after the injection of heparin TF plasma levels and
monocytes PCA significantly decreased (156.5 pg/ml, 74-259 pg/ml and from 1
80 U/10(5) monocytes, 109-582 U/10(5) monocytes to 86.1 U/10(5) monocytes,
28-320 U/10(5) monocytes; - 38% and -55% respectively) and TFPI increased (
235.6 ng/ml, 152-423 ng/ mi; +70%, p<0.001). In conclusion, heparin treatme
nt is associated with a decrease of high TF plasma levels and monocyte proc
oagulant activity in UA patients. These actions of heparin may play a role
in determining the antithrombotic and antiinflammatory properties of this d
rug.